Definium Therapeutics launches GAD education program for providers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026 7:00 AM EDTGAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3
Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4
Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology
NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and... More
